

Temporary benefits added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability Apo-Amitriptyline 10 mg Tablet (DIN 02403137) and Elavil 10 mg Tablet (DIN 00335053) manufactured by AA Pharma Inc., **Mar-Amitriptyline 10 mg Tablet (DIN 02429861)** will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List **December 12, 2023**.

As of **December 12, 2023**, all claims for **Mar-Amitriptyline 10 mg Tablet (DIN 02429861)** will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at ab.bluecross.ca/providers/pharmacy-home.php

Due to the unavailability Teva-Cephalexin 125 (25 mg/mL) Oral Suspension (DIN 00342106) and Teva-Cephalexin 250 (50 mg/mL) Oral Suspension (DIN 00342092), **Lupin-Cephalexin 50 mg/mL Oral Suspension (DIN 02469189)** will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was previously added to the Critical Supply Product List effective **December 9, 2022**.

As of **December 18, 2023**, all claims for **Lupin-Cephalexin 50 mg/mL Oral Suspension (DIN 02469189)** will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at ab.bluecross.ca/providers/pharmacy-home.php

Removal of temporary benefits from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Robitussin Children's Cough and Cold Oral Liquid (DIN 02044013) manufactured by GlaxoSmithKline Consumer Healthcare (Haleon), **Benylin DM-D for Children Oral Syrup (DIN 01944746)** manufactured by McNeil Consumer Healthcare was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Alberta Blue Cross® has confirmed that the shortage for Robitussin Children's Cough and Cold Oral Liquid (DIN 02044013) has been resolved.

Benylin DM-D For Children Oral Syrup (DIN 01944746) will no longer be considered a temporary benefit for the ADBL after **January 16, 2024**. The above grouping was removed from the Critical Supply Product List **December 15, 2023**.

Due to the shortage of Janumet XR 50 mg/1000 mg Extended-Release Tablet (DIN 02416794) manufactured by Merck Canada Inc., **Apo-Sitagliptin/Metformin XR 50 mg/1000 mg Extended-Release Tablet (DIN 02506289)** and **Sandoz Sitagliptin-Metformin XR 50 mg/1000 mg Extended-Release Tablet (DIN 02529114)** were added as temporary benefits for the *Alberta Drug Benefit List (ADBL)*.

Alberta Blue Cross has confirmed that the shortage for Janumet XR 50 mg/1000 mg Extended-Release Tablet (DIN 02416794) has been resolved.

Apo-Sitagliptin/Metformin XR 50 mg/1000 mg Extended-Release Tablet (DIN 02506289) and **Sandoz Sitagliptin-Metformin XR 50 mg/1000 mg Extended-Release Tablet (DIN 02529114)** will no longer be considered temporary benefits for the ADBL after **January 18, 2024**. The above grouping was removed from the Critical Supply Product List **December 18, 2023**.

continued next page

PHARMACY BENEFACT

continued from previous page

Due to the shortage of Valcyte 50 mg/mL Oral Suspension (DIN 02306085) manufactured by Cheplapharm Arzneimittel GMBH Germany, **Auro-Valganciclovir 50 mg/mL Oral Suspension (DIN 02535483)** was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Alberta Blue Cross has confirmed that the shortage for Valcyte 50 mg/mL Oral Suspension (DIN 02306085) has been resolved.

Auro-Valganciclovir 50 mg/mL Oral Suspension (DIN 02535483) will no longer be considered a temporary benefit for the *ADBL* after **January 22, 2024**. The above grouping was removed from the Critical Supply Product List **December 19, 2023**.

Product supply shortage addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has confirmed that the shortage for Sandoz Ciprofloxacin/Dexamethasone Otic Suspension (DIN 02506882) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 17, 2024**. The following grouping was removed from the Critical Supply Product List **December 18, 2023**.

CIPROFLOXACIN HCL / DEXAMETHASONE

0.3% / 0.1% OTIC SUSPENSION

| | | | |
|-------------|------------------------------------|-----|-----------|
| 00002506882 | SANDOZ CIPROFLOXACIN/DEXAMETHASONE | SDZ | \$ 1.9227 |
| 00002481901 | TARO-CIPROFLOXACIN/DEXAMETHASONE | TAR | \$ 1.9227 |
| 00002252716 | CIPRODEX | NOV | \$ 3.8720 |

Removal of temporary benefit from the Palliative Coverage Drug Benefit Supplement (PCDBS)

Due to the shortage of Nozinan 25 mg/mL Injection (DIN 01927698), **Loxapac 50 mg/mL Injection (DIN 02169991)** manufactured by Sandoz Canada Inc. was added as a temporary benefit for the Palliative Coverage Drug Benefit Supplement (PCDBS).

Alberta Blue Cross has confirmed that the shortage Nozinan 25 mg/mL Injection (DIN 01927698) has been resolved.

Loxapac 50 mg/mL Injection (DIN 02169991) will no longer be considered a temporary benefit for the PCDBS after **January 22, 2024**. The above grouping was removed from the Critical Supply Product List **December 20, 2023**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)
403-294-4041 (Calgary and area)
1-800-361-9632 (toll free)
FAX 780-498-8406 (Edmonton and area)
FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

